ACCEPTED MANUSCRIPT
ABBREVIATIONS USED
BzATP, 2'(3')-O-(4-Benzoylbenzoyl)adenosine-5'-triphosphate tri(triethylammonium) salt; DMSO, Dimethyl
sulfoxide; FBS, Fetal bovine serum; HBSS, Hanks’ Balanced Salt Solution; rhIFN-γ, Recombinant human
interferon gamma; LPS, Lipopolysaccharide
REFERENCES
[1] L. Franchi, T. Eigenbrod, R. Munoz-Planillo, G. Nunez, The inflammasome: a caspase-1-activation platform that regulates
immune responses and disease pathogenesis, Nat Immunol, 10 (2009) 241-247.
[2] P. Pelegrin, A. Surprenant, The P2X(7) receptor-pannexin connection to dye uptake and IL-1beta release, Purinergic signalling,
5 (2009) 129-137.
[3] Y. Chakfe, R. Seguin, J.P. Antel, C. Morissette, D. Malo, D. Henderson, P. Séguéla, ADP and AMP Induce Interleukin-1β Release
from Microglial Cells through Activation of ATP-Primed P2X7 Receptor Channels, The Journal of Neuroscience, 22 (2002) 3061-
3069.
[4] L.K. Parvathenani, S. Tertyshnikova, C.R. Greco, S.B. Roberts, B. Robertson, R. Posmantur, P2X7 mediates superoxide
production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease, The Journal of biological
chemistry, 278 (2003) 13309-13317.
[5] P.L. McGeer, E.G. McGeer, The inflammatory response system of brain: implications for therapy of Alzheimer and other
neurodegenerative diseases, Brain research. Brain research reviews, 21 (1995) 195-218.
[6] R. Le Feuvre, D. Brough, N. Rothwell, Extracellular ATP and P2X7 receptors in neurodegeneration, European Journal of
Pharmacology, 447 (2002) 261-269.
[7] A.A. Boucher, J.C. Arnold, G.E. Hunt, A. Spiro, J. Spencer, C. Brown, I.S. McGregor, M.R. Bennett, M. Kassiou, Neuroscience,
189 (2011) 170.
[8] S. Velasquez, J. Rappaport, Inflammasome activation in major depressive disorder: A pivotal linkage between psychological
stress, purinergic signaling, and the kynurenine pathway, Biol. Psychiatry, 80 (2016) 4–5.
[9] C.C. Chrovian, J.C. Rech, A. Bhattacharya, M.A. Letavic, P2X7 antagonists as potential therapeutic agents for the treatment of
CNS disorders, Progress in medicinal chemistry, 53 (2014) 65-100.
[10] A. Bhattacharya, K. Biber, The microglial ATP-gated ion channel P2X7 as a CNS drug target, Glia, 64 (2016) 1772–1787.
[11] T.C. Stock, B.J. Bloom, N. Wei, S. Ishaq, W. Park, X. Wang, P. Gupta, C.A. Mebus, Efficacy and safety of CE-224,535, an
antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate, J.
Rheumatol., 39 (2012) 720–727.
[12] E.C. Keystone, M.M. Wang, M. Layton, S. Hollis, I.B. McInnes, Clinical evaluation of the efficacy of the P2X7 purinergic
receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment
with methotrexate or sulphasalazine, Ann. Rheum. Dis., 71 (2012) 1630–1635.
[13] R. Bartlett, L. Stokes, R. Sluyter, The P2X7 Receptor Channel: Recent Developments and the Use of P2X7 Antagonists in
Models of Disease, Pharmacol. Rev., 66 (2014) 638–675.
[14] A. Baxter, J. Bent, K. Bowers, M. Braddock, S. Brough, M. Fagura, M. Lawson, T. McInally, M. Mortimore, M. Robertson, R.
Weaver, P. Webborn, Hit-to-Lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists, Bioorganic &
medicinal chemistry letters, 13 (2003) 4047-4050.
[15] D.W. Nelson, K. Sarris, D.M. Kalvin, M.T. Namovic, G. Grayson, D.L. Donnelly-Roberts, R. Harris, P. Honore, M.F. Jarvis, C.R.
Faltynek, W.A. Carroll, Structure-activity relationship studies on N'-aryl carbohydrazide P2X7 antagonists, J Med Chem, 51 (2008)
3030-3034.
[16] M.G. Kelly, J. Kincaid, Y. Fang, Y. Cao, C. Kaub, S. Gowlugari, Z. Wang, Bicycloheteroaryl compounds as P2X7 modulators and
uses thereof, in, Google Patents, 2012.
[17] N. Tsuzuki, T. Hama, T. Hibi, R. Konishi, S. Futaki, K. Kitagawa, Adamantane as a brain-directed drug carrier for poorly
absorbed drug: Antinociceptive effects of [D-Ala2] Leu-enkephalin derivatives conjugated with the 1-adamantane moiety,
Biochemical Pharmacology, 41 (1991) R5-R8.
[18] N. Tsuzuki, T. Hama, M. Kawada, A. Hasui, R. Konishi, S. Shiwa, Y. Ochi, S. Futaki, K. Kitagawa, Adamantane as a brain-
directed drug carrier for poorly absorbed drug. 2. AZT derivatives conjugated with the 1-adamantane moiety, Journal of
pharmaceutical sciences, 83 (1994) 481-484.
[19] J. Liu, D. Obando, V. Liao, T. Lifa, R. Codd, The many faces of the adamantyl group in drug design, European journal of
medicinal chemistry, 46 (2011) 1949-1963.
[20] S.M. Wilkinson, H. Gunosewoyo, M.L. Barron, A. Boucher, M. McDonnell, P. Turner, D.E. Morrison, M.R. Bennett, I.S.
McGregor, L.M. Rendina, M. Kassiou, The First CNS-Active Carborane: A Novel P2X7 Receptor Antagonist with Antidepressant
Activity, ACS Chemical Neuroscience, 5 (2014) 335-339.
[21] H. Gunosewoyo, J.L. Guo, M.R. Bennett, M.J. Coster, M. Kassiou, Cubyl amides: novel P2X7 receptor antagonists, Bioorganic &
medicinal chemistry letters, 18 (2008) 3720-3723.
[22] P. Honore, D. Donnelly-Roberts, M.T. Namovic, G. Hsieh, C.Z. Zhu, J.P. Mikusa, G. Hernandez, C. Zhong, D.M. Gauvin, P.
Chandran, R. Harris, A.P. Medrano, W. Carroll, K. Marsh, J.P. Sullivan, C.R. Faltynek, M.F. Jarvis, A-740003 [N-(1-
{[(Cyanoimino)(5-quinolinylamino) methyl]amino}-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a Novel and
Selective P2X7 Receptor Antagonist, Dose-Dependently Reduces Neuropathic Pain in the Rat, Journal of Pharmacology and
Experimental Therapeutics, 319 (2006) 1376-1385.
[23] D.L. Donnelly-Roberts, M.T. Namovic, B. Surber, S.X. Vaidyanathan, A. Perez-Medrano, Y. Wang, W.A. Carroll, M.F. Jarvis,
[3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist
radioligand for P2X7 receptors, Neuropharmacology, 56 (2009) 223-229.
[24] S. Núñez, J. Venhorst, C.G. Kruse, Target–drug interactions: first principles and their application to drug discovery, Drug
Discov. Today, 17 (2012) 10–22.
[25] S. Kapur, P. Seeman, Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for
atypical antipsychotic action, J. Psychiatry Neurosci., 25 (2000) 161–166.
5